Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors [0.03%]
放射性碘难治性和非难治性DTC患者预后差异：一项关于生存率和独立危险因素的队列研究
Menghua Xia,Weifu Lv,Wei Zhao et al.
Menghua Xia et al.
Aims: Patients with distant metastases of differentiated thyroid cancer (DM-DTC) exhibit significant heterogeneity in clinical characteristics and prognosis. This study aimed to investigate prognostic variables affecting ...
Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC" [0.03%]
“enzalutamide与darolutamide双联治疗mHSPC的匹配调整间接比较”述评
Howard Thom,Martin Boegemann,Neal Shore
Howard Thom
Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences [0.03%]
冒烟型多发性骨髓瘤：关于疾病认知和患者治疗偏好的跨国混合方法研究
Matthew Quaife,Cecilia Jimenez-Moreno,Blanca Gros Otero et al.
Matthew Quaife et al.
Aims: To understand disease perceptions and treatment preferences of patients with high-risk smoldering multiple myeloma (HR-SMM) or multiple myeloma (MM) that recently progressed from HR-SMM, and to estimate the minimum ...
A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing [0.03%]
MGMT甲基化检测不可用的情况下IDH野生型胶质母细胞瘤RANO临床风险评分的实用改编
İmdat Eroğlu,Sıla Soylu Koçoğlu,Eron Merovci et al.
İmdat Eroğlu et al.
Background: The novel RANO risk score provides prognostic stratification for patients with IDH-wildtype glioblastoma(GBM) and includes age, Karnofsky Performance Scale(KPS), RANO resection class(RRC), and MGMT promoter me...
Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study [0.03%]
中国早期乳腺癌患者蒽环类药物诱发的心脏毒性的临床及基因危险因素：候选基因研究
Shan Xu,Hao Yang,Nan Hu
Shan Xu
Purpose: This study aimed to clarify the incidence of anthracycline-induced cardiotoxicity (ACT) and identify its clinical and candidate genetic risk factors in Chinese early-stage breast cancer patients, so as to provide...
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS [0.03%]
TroFuse-011研究设计：用于PD-L1 CPS阳性晚期三阴性乳腺癌的Sacituzumab Govitecan单药或联合Pembrolizumab治疗
Hope S Rugo,Peter Schmid,Javier Cortes et al.
Hope S Rugo et al.
Patients with advanced TNBC with PD-L1 CPS < 10 are typically treated with chemotherapy and experience poor outcomes. Sacituzumab tirumotecan (sac-TMT; MK-2870/SKB264) is a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug c...
Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries [0.03%]
七国复发/难治性边缘区淋巴瘤的治疗模式：真实世界证据
Harshali Patel,Lynn Huynh,Patrick Squires et al.
Harshali Patel et al.
Background: Given the rarity of marginal zone lymphoma (MZL), real-world data on relapsed/refractory (R/R) MZL are limited. Methods: Th...
Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States [0.03%]
估计的与使用伊布替尼和zanubrutinib治疗慢性淋巴细胞白血病相关的心脏病死亡率——基于美国患者的分析结果
Jennifer R Brown,Talha Munir,Andrew H Lipsky et al.
Jennifer R Brown et al.
Background: In the absence of real-world comparative studies of cardiac death risk, this study estimates the potential reduction in cardiac mortality associated with treating chronic lymphocytic leukemia (CLL) patients wi...
Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience [0.03%]
帕博利珠单抗一线治疗转移性非小细胞肺癌的现实世界疗效：十年证据和经验
Riddhi A Babel,Stephen V Liu,Tao Fan et al.
Riddhi A Babel et al.
Non-small cell lung cancer (NSCLC) remains a global burden, particularly due to late‑stage diagnosis. Immune checkpoint inhibitors (ICIs) for mNSCLC, including first-line (1L) pembrolizumab regimens, significantly improved survival for the...
Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer [0.03%]
用于转移性激素敏感型前列腺癌患者的恩扎卢胺与阿帕鲁胺匹配调整的间接比较：与雄激素剥夺治疗相比
Arun A Azad,Bhavik J Pandya,Hemant Singh Bhadauria et al.
Arun A Azad et al.
Aims: To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus apalutamide + ADT in metastatic hormone-sensitive prostate cancer (mHSPC) using a matching-adjusted indirect comparison (MAIC). ...